In this short, chaptered video programme, Dr Chad Deal, Head of the Center for Osteoporosis and Metabolic Bone Disease at the Cleveland Clinic, shares practical insights to help clinicians identify patients with hypophosphatasia (HPP).

 

Despite being a lifelong metabolic condition, HPP is often under-recognised, especially in adults. Dr Deal discusses the importance of distinguishing HPP from other musculoskeletal and rheumatic diseases that HPP commonly disguises itself as, including osteoporosis, fibromyalgia, pseudogout, and arthritis-like conditions1-5. He also explains how understanding the clinical presentation, recognising HPP signs and symptoms, and taking a detailed patient and family history can support timely diagnosis and appropriate care.

 

Watch the full video or browse by chapter using the tabs below.

In this short, chaptered video programme, Dr Chad Deal, Head of the Center for Osteoporosis and Metabolic Bone Disease at the Cleveland Clinic, shares practical insights to help clinicians identify, patients with hypophosphatasia (HPP).

 

Despite being a lifelong metabolic condition, HPP is often under-recognised, especially in adults. Dr Deal discusses the importance of distinguishing HPP from other musculoskeletal and rheumatic diseases that HPP commonly disguises itself as, including osteoporosis, fibromyalgia, pseudogout, and arthritis-like conditions1-5. He also explains how understanding the clinical presentation, recognising HPP signs and symptoms, and taking a detailed patient and family history can support timely diagnosis and appropriate care.

 

Watch the full video or browse by chapter using the tabs below.

In this short, chaptered video programme, Dr Chad Deal, Head of the Center for Osteoporosis and Metabolic Bone Disease at the Cleveland Clinic, shares practical insights to help clinicians identify, patients with hypophosphatasia (HPP).

 

Despite being a lifelong metabolic condition, HPP is often under-recognised, especially in adults. Dr Deal discusses the importance of distinguishing HPP from other musculoskeletal and rheumatic diseases that HPP commonly disguises itself as, including osteoporosis, fibromyalgia, pseudogout, and arthritis-like conditions1-5. He also explains how understanding the clinical presentation, recognising HPP signs and symptoms, and taking a detailed patient and family history can support timely diagnosis and appropriate care.

 

Watch the full video or browse by chapter using the tabs below.

In this short, chaptered video programme, Dr Chad Deal, Head of the Center for Osteoporosis and Metabolic Bone Disease at the Cleveland Clinic, shares practical insights to help clinicians identify, patients with hypophosphatasia (HPP).

 

Despite being a lifelong metabolic condition, HPP is often under-recognised, especially in adults. Dr Deal discusses the importance of distinguishing HPP from other musculoskeletal and rheumatic diseases that HPP commonly disguises itself as, including osteoporosis, fibromyalgia, pseudogout, and arthritis-like conditions1-5. He also explains how understanding the clinical presentation, recognising HPP signs and symptoms, and taking a detailed patient and family history can support timely diagnosis and appropriate care.

 

Watch the full video or browse by chapter using the tabs below.

In this short, chaptered video programme, Dr Chad Deal, Head of the Center for Osteoporosis and Metabolic Bone Disease at the Cleveland Clinic, shares practical insights to help clinicians identify, patients with hypophosphatasia (HPP).

 

Despite being a lifelong metabolic condition, HPP is often under-recognised, especially in adults. Dr Deal discusses the importance of distinguishing HPP from other musculoskeletal and rheumatic diseases that HPP commonly disguises itself as, including osteoporosis, fibromyalgia, pseudogout, and arthritis-like conditions1-5. He also explains how understanding the clinical presentation, recognising HPP signs and symptoms, and taking a detailed patient and family history can support timely diagnosis and appropriate care.

 

Watch the full video or browse by chapter using the tabs below.

Dr Chad Deal shares his insights on:

  • Recognising presentations of HPP, including key symptoms and common misdiagnoses (Chapter 1)
  • HPP diagnosis and earlier recognition of HPP signs and symptoms and the impact of deficient ALP  (Chapter 2)
  • The role of family history in identifying other affected individuals with HPP (Chapter 3)
  • The evolution of our understanding that led us to rethink HPP (Chapter 4)

 

Next:

  • View 5 fact cards here to reveal key statistics and clinical insights on the diagnosis and disease burden of (HPP) in children and adults. Will they make you rethink HPP diagnosis and disease burden?
  • Watch a short animated video on rethinking HPP disease burden and the systemic impacts of deficient alkaline phosphate activity

 

1.Bangura A, et al. Cureus. 2020;12(6):e8594; 2. Braunstein NA. Bone Rep. 2015;4:1–4; 3. Nunes ME. Hypophosphatasia. 2007 Nov 20 [Updated 2023 Mar 30]. In Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 4. Rush et al Osteoporosis International (2024) 35:1–10 5. Khan et al Osteoporosis International (2023) 35:431–438

Dr Chad Deal is the head of the Center for Osteoporosis and Metabolic Bone Disease at The Cleveland Clinic in Ohio.

 

A practicing rheumatologist at The Cleveland Clinic, he is a board certified in rheumatology and internal medicine.

 

Dr Deal did his undergraduate work at Washington University in St. Louis. He attended medical school at the University of Arkansas, was Alpha Omega Alpha, and graduated in 1977. His internship and residency were at Boston City Hospital in Massachusetts. He completed a fellowship in arthritis and connective tissue diseases at Boston University School of Medicine in 1982.

 

Dr Deal has been in Cleveland since 1984. He was an associate professor of medicine at the Case Western Reserve University School of Medicine until 1999 when he left to join The Cleveland Clinic.

 

He has been an active investigator in multiple clinical trials relating to arthritis and osteoporosis and is author of more than 70 publications. Dr Deal is a Master of the American College of Rheumatology and is an Associate Editor for Arthritis and Rheumatology.

Dr Chad Deal has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Alexion Pharmaceuticals and Radius Health

Dr Chad Deal shares his insights on:

  • Recognising presentations of HPP, including key symptoms and common misdiagnoses (Chapter 1)
  • HPP diagnosis and earlier recognition of HPP signs and symptoms and the impact of deficient ALP  (Chapter 2)
  • The role of family history in identifying other affected individuals with HPP (Chapter 3)
  • The evolution of our understanding that led us to rethink HPP (Chapter 4)

Next:

  • View 5 fact cards here to reveal key statistics and clinical insights on the diagnosis and disease burden of (HPP) in children and adults. Will they make you rethink HPP diagnosis and disease burden?
  • Watch a short animated video on rethinking HPP disease burden and the systemic impacts of deficient alkaline phosphate activity

 

1.Bangura A, et al. Cureus. 2020;12(6):e8594; 2. Braunstein NA. Bone Rep. 2015;4:1–4; 3. Nunes ME. Hypophosphatasia. 2007 Nov 20 [Updated 2023 Mar 30]. In Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 4. Rush et al Osteoporosis International (2024) 35:1–10 5. Khan et al Osteoporosis International (2023) 35:431–438

Dr Chad Deal is the head of the Center for Osteoporosis and Metabolic Bone Disease at The Cleveland Clinic in Ohio.

 

A practicing rheumatologist at The Cleveland Clinic, he is a board certified in rheumatology and internal medicine.

 

Dr Deal did his undergraduate work at Washington University in St. Louis. He attended medical school at the University of Arkansas, was Alpha Omega Alpha, and graduated in 1977. His internship and residency were at Boston City Hospital in Massachusetts. He completed a fellowship in arthritis and connective tissue diseases at Boston University School of Medicine in 1982.

 

Dr Deal has been in Cleveland since 1984. He was an associate professor of medicine at the Case Western Reserve University School of Medicine until 1999 when he left to join The Cleveland Clinic.

 

He has been an active investigator in multiple clinical trials relating to arthritis and osteoporosis and is author of more than 70 publications. Dr Deal is a Master of the American College of Rheumatology and is an Associate Editor for Arthritis and Rheumatology.

Dr Chad Deal has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Alexion Pharmaceuticals and Radius Health

Dr Chad Deal shares his insights on:

  • Recognising presentations of HPP, including key symptoms and common misdiagnoses (Chapter 1)
  • HPP diagnosis and earlier recognition of HPP signs and symptoms and the impact of deficient ALP  (Chapter 2)
  • The role of family history in identifying other affected individuals with HPP (Chapter 3)
  • The evolution of our understanding that led us to rethink HPP (Chapter 4)

Next:

  • View 5 fact cards here to reveal key statistics and clinical insights on the diagnosis and disease burden of (HPP) in children and adults. Will they make you rethink HPP diagnosis and disease burden?
  • Watch a short animated video on rethinking HPP disease burden and the systemic impacts of deficient alkaline phosphate activity

 

1.Bangura A, et al. Cureus. 2020;12(6):e8594; 2. Braunstein NA. Bone Rep. 2015;4:1–4; 3. Nunes ME. Hypophosphatasia. 2007 Nov 20 [Updated 2023 Mar 30]. In Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 4. Rush et al Osteoporosis International (2024) 35:1–10 5. Khan et al Osteoporosis International (2023) 35:431–438

Dr Chad Deal is the head of the Center for Osteoporosis and Metabolic Bone Disease at The Cleveland Clinic in Ohio.

 

A practicing rheumatologist at The Cleveland Clinic, he is a board certified in rheumatology and internal medicine.

 

Dr Deal did his undergraduate work at Washington University in St. Louis. He attended medical school at the University of Arkansas, was Alpha Omega Alpha, and graduated in 1977. His internship and residency were at Boston City Hospital in Massachusetts. He completed a fellowship in arthritis and connective tissue diseases at Boston University School of Medicine in 1982.

 

Dr Deal has been in Cleveland since 1984. He was an associate professor of medicine at the Case Western Reserve University School of Medicine until 1999 when he left to join The Cleveland Clinic.

 

He has been an active investigator in multiple clinical trials relating to arthritis and osteoporosis and is author of more than 70 publications. Dr Deal is a Master of the American College of Rheumatology and is an Associate Editor for Arthritis and Rheumatology.

Dr Chad Deal has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Alexion Pharmaceuticals and Radius Health

Dr Chad Deal shares his insights on:

  • Recognising presentations of HPP, including key symptoms and common misdiagnoses (Chapter 1)
  • HPP diagnosis and earlier recognition of HPP signs and symptoms and the impact of deficient ALP  (Chapter 2)
  • The role of family history in identifying other affected individuals with HPP (Chapter 3)
  • The evolution of our understanding that led us to rethink HPP (Chapter 4)

 

Next:

  • View 5 fact cards here to reveal key statistics and clinical insights on the diagnosis and disease burden of (HPP) in children and adults. Will they make you rethink HPP diagnosis and disease burden?
  • Watch a short animated video on rethinking HPP disease burden and the systemic impacts of deficient alkaline phosphate activity

 

1.Bangura A, et al. Cureus. 2020;12(6):e8594; 2. Braunstein NA. Bone Rep. 2015;4:1–4; 3. Nunes ME. Hypophosphatasia. 2007 Nov 20 [Updated 2023 Mar 30]. In Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 4. Rush et al Osteoporosis International (2024) 35:1–10 5. Khan et al Osteoporosis International (2023) 35:431–438

Dr Chad Deal shares his insights on:

  • Recognising presentations of HPP, including key symptoms and common misdiagnoses (Chapter 1)
  • HPP diagnosis and earlier recognition of HPP signs and symptoms and the impact of deficient ALP  (Chapter 2)
  • The role of family history in identifying other affected individuals with HPP (Chapter 3)
  • The evolution of our understanding that led us to rethink HPP (Chapter 4)

 

Next:

  • View 5 fact cards here to reveal key statistics and clinical insights on the diagnosis and disease burden of (HPP) in children and adults. Will they make you rethink HPP diagnosis and disease burden?
  • Watch a short animated video on rethinking HPP disease burden and the systemic impacts of deficient alkaline phosphate activity

 

1.Bangura A, et al. Cureus. 2020;12(6):e8594; 2. Braunstein NA. Bone Rep. 2015;4:1–4; 3. Nunes ME. Hypophosphatasia. 2007 Nov 20 [Updated 2023 Mar 30]. In Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 4. Rush et al Osteoporosis International (2024) 35:1–10 5. Khan et al Osteoporosis International (2023) 35:431–438

Dr Chad Deal is the head of the Center for Osteoporosis and Metabolic Bone Disease at The Cleveland Clinic in Ohio.

 

A practicing rheumatologist at The Cleveland Clinic, he is a board certified in rheumatology and internal medicine.

 

Dr Deal did his undergraduate work at Washington University in St. Louis. He attended medical school at the University of Arkansas, was Alpha Omega Alpha, and graduated in 1977. His internship and residency were at Boston City Hospital in Massachusetts. He completed a fellowship in arthritis and connective tissue diseases at Boston University School of Medicine in 1982.

 

Dr Deal has been in Cleveland since 1984. He was an associate professor of medicine at the Case Western Reserve University School of Medicine until 1999 when he left to join The Cleveland Clinic.

 

He has been an active investigator in multiple clinical trials relating to arthritis and osteoporosis and is author of more than 70 publications. Dr Deal is a Master of the American College of Rheumatology and is an Associate Editor for Arthritis and Rheumatology.

Dr Chad Deal has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Alexion Pharmaceuticals and Radius Health

Programme summary
  • clock Duration 2 MIN
  • clock Language(s) flag
Watch the video now
Share this programme

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

Supporter Acknowledgement

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

I agree that this programme:

Was valuable to me

1/3
Programme summary
  • clock Duration 3 MIN
  • clock Language(s) flag
Watch the video now
Share this programme

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

Supporter Acknowledgement

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

I agree that this programme:

Was valuable to me

1/3
Programme summary
  • clock Duration 1 MIN
  • clock Language(s) flag
Watch the video now
Share this programme

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

Supporter Acknowledgement

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

I agree that this programme:

Was valuable to me

1/3
Programme summary
  • clock Duration 2 MIN
  • clock Language(s) flag
Watch the video now
Share this programme

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

Supporter Acknowledgement

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

I agree that this programme:

Was valuable to me

1/3
Programme summary
  • clock Duration 11 MIN
  • clock Language(s) flag
Watch the video now
Share this programme

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

Supporter Acknowledgement

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only. 

Alexion

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved. GL/UNB-H/0069

I agree that this programme:

Was valuable to me

1/3

Other programmes of interest

patient-support Patient Support
Rare diseases 
Understanding narcolepsy

Persistent sleepiness: when to look closer

Experts
Prof. Yves Dauvilliers
Endorsed by
EU-NN ANC
eNAP
  • clock 2 MIN
  • calendar Jan 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Takeda
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
podcast Video podcast
Oncology Endocrinology Rare diseases 
Understanding EP-NEC: Through diagnosis, treatment, and support

A medical oncologist and a patient advocate share their perspectives

Experts
Dr Aman Chauhan, Susan Meckler-Plummer, RN
Endorsed by
Minkhas mission Neuroendocrine Cancer UK Neuroendocrine Cancer Foundation
NET-Research-Foundation
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Nov 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
podcast Video podcast
Oncology Endocrinology Rare diseases 
Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts
Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)
Endorsed by
NANETS
CommNETs Neuroendocrine Cancer UK
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from ITM.
animated-video Animated Video
Endocrinology Rare diseases Bone diseases 
Rethinking hypophosphatasia (HPP) and systemic impacts of deficient alkaline phosphatase activity

Understanding the mechanism of disease of hypophosphatasia

  • clock 4 MIN
  • calendar May 2025

This programme has been initiated and funded by Alexion Pharmaceuticals and is intended for healthcare professionals only.  The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.©2024 Alexion Pharmaceuticals, Inc. All rights reserved.GL/UNB-H/0063 – May 2025